Normalization of visceral adiposity is required to normalize plasma apolipoprotein B levels in response to a healthy eating/physical activity lifestyle modification program in viscerally obese men

Atherosclerosis

Volumn 221, Issue 2, 2012, Pages 577-582

  Pelletier Beaumont, Emilie ^a,b   Arsenault, Benoit J ^a   Alméras, Natalie ^a   Bergeron, Jean ^c   Tremblay, Angelo ^a,b   Poirier, Paul ^a,b   Després, Jean Pierre ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c Université Laval   (Canada)

Author keywords

Apolipoproteins B; Exercise; Lifestyle intervention; Visceral adipose tissue

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTHROPOMETRY; ARTICLE; ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EATING; HUMAN; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUTRITION; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; VISCERAL ADIPOSITY;

ADIPOSITY; ADULT; AGED; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CALORIC RESTRICTION; DYSLIPIDEMIAS; EXERCISE; FOOD HABITS; HUMANS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; QUEBEC; REFERENCE VALUES; REGRESSION ANALYSIS; RISK REDUCTION BEHAVIOR; SEX FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84858701666     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.01.023     Document Type: Article

References (39)

1. Haffner S.M. Risk factors for non-insulin-dependent diabetes mellitus. J Hypertens Suppl 1995, 13:S73-S76.
2. Dagenais G.R., Yi Q., Mann J.F., et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005, 149:54-60.
3. Boden G., Cheung P., Stein T.P., et al. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab 2002, 283:E12-E19.
4. Sniderman A.D., Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb 1993, 13:629-636.
5. Riches F.M., Watts G.F., Naoumova R.P., et al. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord 1998, 22:414-423.
6. Borkan G.A., Gerzof S.G., Robbins A.H., et al. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 1982, 36:172-177.
7. Sniderman A.D., Scantlebury T., Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001, 135:447-459.
8. Arsenault B.J., Boekholdt S.M., Kastelein J.J. Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol 2011, 8:197-206.
9. Ginsberg H.N., Zhang Y.L., Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 2006, 14(Suppl 1):41S-49S.
10. Sniderman A.D., Williams K., Contois J.H., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4:337-345.
11. Lamarche B., Moorjani S., Lupien P.J., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996, 94:273-278.
12. Pedersen T.R., Olsson A.G., Faergeman O., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998, 97:1453-1460.
13. Simes R.J., Marschner I.C., Hunt D., et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 2002, 105:1162-1169.
14. Hainer V., Toplak H., Mitrakou A. Treatment modalities of obesity: what fits whom?. Diabetes Care 2008, 31(Suppl 2):S269-S277.
15. Ross R., Dagnone D., Jones P.J., et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000, 133:92-103.
16. Watkins L.L., Sherwood A., Feinglos M., et al. Effects of exercise and weight loss on cardiac risk factors associated with syndrome X. Arch Intern Med 2003, 163:1889-1895.
17. Després J.P., Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev 1993, 6:137-159.
18. Cornier M.A., Després J.P., Davis N., et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation 2011.
19. Lemieux I., Pascot A., Couillard C., et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation 2000, 102:179-184.
20. The Airlie (VA) Consensus Conference: Standardization of Anthropometric Measurements 1988, 39-80. Human Kinetics Publishers, Champaign, Illinois. T.R.A. Lohman, R. Martorell (Eds.).
21. van der Kooy K., Leenen R., Seidell J.C., et al. Abdominal diameters as indicators of visceral fat: comparison between magnetic resonance imaging and anthropometry. Br J Nutr 1993, 70:47-58.
22. Ferland M., Després J.P., Tremblay A., et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 1989, 61:139-148.
23. Després J.P., Ross R., Boka G., et al. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-lipids trial. Arterioscler Thromb Vasc Biol 2009, 29:416-423.
24. Allain C.C., Poon L.S., Chan C.S., et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974, 20:470-475.
25. Fossati P., Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982, 28:2077-2080.
26. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
27. Ross R., Aru J., Freeman J., et al. Abdominal adiposity and insulin resistance in obese men. Am J Physiol Endocrinol Metab 2002, 282:E657-E663.
28. Howard B.V. Insulin Actions In Vivo: Insulin and Lipoprotein Metabolism. International Textbook of Diabetes Mellitus 1995, John Wiley & Sons, West Sussex, UK. 2nd ed.
29. Leiter L.A., Fitchett D.H., Gilbert R.E., et al. Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). Can J Cardiol 2011, 27:124-131.
30. Naoumova R.P., Cummings M.H., Watts G.F., et al. Acute hyperinsulinaemia decreases cholesterol synthesis less in subjects with non-insulin-dependent diabetes mellitus than in non-diabetic subjects. Eur J Clin Invest 1996, 26:332-340.
31. Howard B.V., Ruotolo G., Robbins D.C. Obesity and dyslipidemia. Endocrinol Metab Clin North Am 2003, 32:855-867.
32. Borel A.L., Nazare J.A., Smith J., et al. Improvement in insulin sensitivity following a 1-year lifestyle intervention program in viscerally obese men: contribution of abdominal adiposity. Metabolism 2012, 61:262-272.
33. Holme I., Hostmark A.T., Anderssen S.A. ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men, results from the 1-year randomized Oslo Diet and Exercise Study. J Intern Med 2007, 262:235-243.
34. O'Donovan G., Owen A., Kearney E.M., et al. Cardiovascular disease risk factors in habitual exercisers, lean sedentary men and abdominally obese sedentary men. Int J Obes (Lond) 2005, 29:1063-1069.
35. Riches F.M., Watts G.F., Hua J., et al. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 1999, 84:2854-2861.
36. Bertrand O.F., Poirier P., Rodes-Cabau J., et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: a randomized placebo-controlled clinical trial. Atherosclerosis 2010, 211:565-573.
37. Arner P. Regional adipocity in man. J Endocrinol 1997, 155:191-192.
38. Kadowaki T., Sekikawa A., Murata K., et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int J Obes (Lond) 2006, 30:1163-1165.
39. Hoffman D.J., Wang Z., Gallagher D., et al. Comparison of visceral adipose tissue mass in adult African Americans and whites. Obes Res 2005, 13:66-74.